BACKGROUND: The prognosis for breast cancer patients overexpressing human epidermal growth factor receptor (HER)-2 has changed with anti-HER-2-targeted therapy. Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving. METHODS: A literature review of well-established and recently published trials, reviews, and ongoing clinical trials addressing first-line treatment for HER-2(+) metastatic breast cancer patients was performed. RESULTS: Taxanes are the agents most commonly used in combination with trastuzumab, but other chemotherapy drugs, such as anthracyclines, vinorelbine, and gemcitabine and triple-combination therapies including platinum compounds, capecitabine, and taxanes have been studied. The combination of aromatase inhibitors with anti-HER-2 therapies is a new therapeutic option for some patients who coexpress HER-2 and hormone receptors, although its activity observed in randomized clinical trials seems to be inferior to that of chemotherapy plus anti-HER-2 therapies. In addition, new anti-HER-2 therapies have shown activity in HER-2(+) tumors, both alone and in combination with trastuzumab. CONCLUSIONS: Trastuzumab plus chemotherapy is the current standard of care for the upfront treatment of HER-2(+) breast cancer patients, though other anti-HER-2-targeting agents may appear as new standards in the upcoming years.
BACKGROUND: The prognosis for breast cancerpatients overexpressing humanepidermal growth factor receptor (HER)-2 has changed with anti-HER-2-targeted therapy. Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving. METHODS: A literature review of well-established and recently published trials, reviews, and ongoing clinical trials addressing first-line treatment for HER-2(+) metastatic breast cancerpatients was performed. RESULTS:Taxanes are the agents most commonly used in combination with trastuzumab, but other chemotherapy drugs, such as anthracyclines, vinorelbine, and gemcitabine and triple-combination therapies including platinum compounds, capecitabine, and taxanes have been studied. The combination of aromatase inhibitors with anti-HER-2 therapies is a new therapeutic option for some patients who coexpress HER-2 and hormone receptors, although its activity observed in randomized clinical trials seems to be inferior to that of chemotherapy plus anti-HER-2 therapies. In addition, new anti-HER-2 therapies have shown activity in HER-2(+) tumors, both alone and in combination with trastuzumab. CONCLUSIONS:Trastuzumab plus chemotherapy is the current standard of care for the upfront treatment of HER-2(+) breast cancerpatients, though other anti-HER-2-targeting agents may appear as new standards in the upcoming years.
Authors: Denise A Yardley; Howard A Burris; Lisa Simons; David R Spigel; F Anthony Greco; John H Barton; Dianna Shipley; David Drosick; John D Hainsworth Journal: Clin Breast Cancer Date: 2008-10 Impact factor: 3.225
Authors: Angelo Di Leo; Henry L Gomez; Zeba Aziz; Zanete Zvirbule; Jose Bines; Michael C Arbushites; Stephanie F Guerrera; Maria Koehler; Cristina Oliva; Steven H Stein; Lisa S Williams; Judy Dering; Richard S Finn; Michael F Press Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544
Authors: Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Kwok-K Wong; Paula M Fracasso; Ronald M Bukowski; Thomas J Lynch; Pamela N Munster; Geoffrey I Shapiro; Pasi A Jänne; Joseph P Eder; Michael J Naughton; Matthew J Ellis; Suzanne F Jones; Tarek Mekhail; Charles Zacharchuk; Jennifer Vermette; Richat Abbas; Susan Quinn; Christine Powell; Howard A Burris Journal: Clin Cancer Res Date: 2009-03-24 Impact factor: 12.531
Authors: Javier Cortes; Serena Di Cosimo; Miguel A Climent; Hernán Cortés-Funes; Ana Lluch; Pere Gascón; José I Mayordomo; Miguel Gil; Manuel Benavides; Lluís Cirera; Belén Ojeda; César A Rodríguez; José M Trigo; Josep Vazquez; Pilar Regueiro; Juan F Dorado; José Baselga Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531
Authors: M Scaltriti; C Verma; M Guzman; J Jimenez; J L Parra; K Pedersen; D J Smith; S Landolfi; S Ramon y Cajal; J Arribas; J Baselga Journal: Oncogene Date: 2008-12-08 Impact factor: 9.867
Authors: Teemu T Junttila; Robert W Akita; Kathryn Parsons; Carter Fields; Gail D Lewis Phillips; Lori S Friedman; Deepak Sampath; Mark X Sliwkowski Journal: Cancer Cell Date: 2009-05-05 Impact factor: 31.743
Authors: Gail D Lewis Phillips; Guangmin Li; Debra L Dugger; Lisa M Crocker; Kathryn L Parsons; Elaine Mai; Walter A Blättler; John M Lambert; Ravi V J Chari; Robert J Lutz; Wai Lee T Wong; Frederic S Jacobson; Hartmut Koeppen; Ralph H Schwall; Sara R Kenkare-Mitra; Susan D Spencer; Mark X Sliwkowski Journal: Cancer Res Date: 2008-11-15 Impact factor: 13.312
Authors: Noelia Martínez-Jañez; Ignacio Chacón; Ana de Juan; Luis Cruz-Merino; Sònia Del Barco; Isaura Fernández; Paula García-Teijido; Amalia Gómez-Bernal; Arrate Plazaola; José Ponce; Sonia Servitja; Pilar Zamora Journal: Breast Care (Basel) Date: 2016-02-08 Impact factor: 2.860
Authors: Julie C Friedland; Donald L Smith; Jim Sang; Jaime Acquaviva; Suqin He; Chaohua Zhang; David A Proia Journal: Invest New Drugs Date: 2013-05-18 Impact factor: 3.850